Merus NV
MRUS66.580USD
+1.020+1.56%
交易中 （美東）報價延遲15分鐘
4.61B總市值
虧損本益比TTM
關於 Merus NV 公司
Merus NV 是一家總部位於荷蘭的生物技術公司，專注於爲癌症患者開發差異化療法。Merus 的產品線基於 Multiclonics 格式。其產品旨在與多個靶標結合，並具有抗癌作用，可對抗驅動癌症的複雜機制。該公司的產品利用技術平臺與癌症抗原結合，並利用免疫系統的力量殺死腫瘤細胞。其中一種藥物 zenocutuzumab (Zeno) 是一種 Biclonics 抗體，專注於幫助肺癌、胰腺癌和其他類型實體瘤患者。該公司在荷蘭和美國開展業務。
公司簡介
公司代碼MRUS
公司名稱Merus NV
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
員工數量260
證券類型Ordinary Share
年結日May 19
公司地址Uppsalalaan 17, 3rd & 4th floor
城市UTRECHT
上市交易所NASDAQ Global Market Consolidated
國家Netherlands
郵編3584 CT
電話31850162500
網址https://merus.nl/
公司代碼MRUS
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
35.42%
Hedge Fund
34.84%
Investment Advisor
23.80%
Corporation
1.96%
Research Firm
1.56%
Venture Capital
1.48%
Private Equity
1.43%
Individual Investor
0.38%
Pension Fund
0.36%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
409
75.54M
101.47%
-10.37M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
Samlyn Capital, LLC
2.38M
3.2%
-288.75K
-10.82%
Mar 31, 2025
Franklin Advisers, Inc.
1.94M
2.6%
+3.50K
+0.18%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Tema Oncology ETF
3.92%
ALPS Medical Breakthroughs ETF
2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.51%
Harbor Health Care ETF
1.1%
First Trust IPOX Europe Equity Opportunities ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
JPMorgan Healthcare Leaders ETF
0.62%
ProShares Ultra Nasdaq Biotechnology
0.41%
Invesco Nasdaq Biotechnology ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.39%
查看更多
Tema Oncology ETF
佔比3.92%
ALPS Medical Breakthroughs ETF
佔比2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.51%
Harbor Health Care ETF
佔比1.1%
First Trust IPOX Europe Equity Opportunities ETF
佔比1.04%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.85%
JPMorgan Healthcare Leaders ETF
佔比0.62%
ProShares Ultra Nasdaq Biotechnology
佔比0.41%
Invesco Nasdaq Biotechnology ETF
佔比0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.39%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
